Patents by Inventor Parva Yogeshchandra Purohit
Parva Yogeshchandra Purohit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240077483Abstract: The invention provided herein a pharmaceutical process used for an extraction of proteins from pancreatic sample and estimation of the extracted proteins. Moreover, the invention provides a use of suitable is selected from citrate-phosphate buffer and bicarbonate buffer capable to extract proteins from pancreatic sample. The invention further provides an analytical method to perform estimation of extracted proteins. This process provides an improved extraction method to quantify protein present in the pancreatic sample.Type: ApplicationFiled: March 23, 2022Publication date: March 7, 2024Inventors: Raja Reddy Kuppili, Chintan Mineshkumar Vaywala, Parva Yogeshchandra Purohit, Mukesh Mahajan, Sanjaykumar Vanrajbhat Talpara
-
Publication number: 20240069025Abstract: The present invention provides an improved method for analysis of pancreatic protein mixture comprises at least more than one biological active protein selected from amylase, protease and lipase, wherein the analysis and quantification of pancreatic protein mixtures is performed with Size Exclusion High Performance Liquid Chromatography (SE-HPLC). Also, the present invention provides the process for the separation, analysis and quantification of low molecular weight and high molecular weight enzymes present in pancreatic protein mixture.Type: ApplicationFiled: March 23, 2022Publication date: February 29, 2024Inventors: Raja Reddy Kuppili, Roshan Ganeshial Upadhyay, Parva Yogeshchandra Purohit, Mukesh Mahajan, Sanjaykumar Vanrajbhat Talpara
-
Patent number: 11760741Abstract: The present invention is directed to pro-drugs of Eliglustat (formula A) and process for the preparation thereof. The present invention is further directed to pharmaceutical composition thereof and method of treatment using the same.Type: GrantFiled: May 2, 2019Date of Patent: September 19, 2023Assignee: KASHIV BIOSCIENCES, LLCInventors: Parva Yogeshchandra Purohit, Pathik Subhashchandra Brahmkshatriya
-
Publication number: 20230137764Abstract: The present invention relates to Fulvestrant prodrugs and process for the preparation thereof. The present disclosure also relates to pharmaceutical composition of Fulvestrant prodrugs and method of treatment using the same.Type: ApplicationFiled: November 24, 2020Publication date: May 4, 2023Inventors: Parva Yogeshchandra PUROHIT, Pathik Subhashchandra BRAHMKSHATRIYA, Vishalgiri Gunvantgiri GOSWAMI
-
Patent number: 11285152Abstract: The present invention relates to a stable orally disintegrating pharmaceutical formulation comprising imatinib or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. The present invention further relates to a stable dispersible pharmaceutical formulation comprising imatinib or a pharmaceutically acceptable salt thereof, and a one or more pharmaceutically acceptable excipients. Moreover, the present invention also relates to a novel pharmaceutical sachet formulation comprising an effective amount of imatinib or a pharmaceutically acceptable salt thereof, a flavouring agent, a sweetener and a one or more pharmaceutically acceptable excipients.Type: GrantFiled: July 16, 2018Date of Patent: March 29, 2022Assignee: KASHIV BIOSCIENCES, LLCInventors: Parva Yogeshchandra Purohit, Paras Rasiklal Vasanani, Vikas Maheshbhai Agrawal, Kiran Dilipbhai Patel
-
Publication number: 20210300887Abstract: The present invention is directed to pro-drugs of Eliglustat (formula A) and process for the preparation thereof. The present invention is further directed to pharmaceutical composition thereof and method of treatment using the same.Type: ApplicationFiled: May 2, 2019Publication date: September 30, 2021Inventors: Parva Yogeshchandra PUROHIT, Pathik Subhashchandra BRAHMKSHATRIYA
-
Publication number: 20210253626Abstract: The present invention relates to fulvestrant prodrugs of formula II and process for the preparation thereof. The present disclosure also relates to pharmaceutical composition of fulvestrant prodrugs and method of treatment using the same.Type: ApplicationFiled: May 24, 2019Publication date: August 19, 2021Inventors: Parva Yogeshchandra PUROHIT, Pathik Subhashchandra BRAHMKSHATRIYA, Vishalgiri Gunvantgiri GOSWAMI
-
Publication number: 20210161846Abstract: The present invention relates to a pharmaceutical composition comprising penicillamine which remains stable for a longer period of time at room temperature. The present invention specifically addresses problem associated with impurity generation during a penicillamine composition preparation and bad odour of penicillamine active ingredient. The pharmaceutical composition of present invention comprises penicillamine and one or more pharmaceutically acceptable excipients wherein the said composition is present in liquid dosage form. Moreover, the present invention composition provides patient compliance aspect in the treatment of Wilson's disease, Rheumatoid Arthritis and Cystinuria.Type: ApplicationFiled: December 6, 2018Publication date: June 3, 2021Inventors: Parva Yogeshchandra PUROHIT, Paras Rasiklal VASANANI, Vikas Maheshbhai AGRAWAL, Jitendra Shantilal PATEL, Nisha Ganapatbhai PATEL
-
Publication number: 20210077451Abstract: The present invention relates to a pharmaceutical composition of ferric citrate or a pharmaceutically acceptable salt and one or more pharmaceutically acceptable excipients. The present invention specifically relates to oral pharmaceutical composition of ferric citrate and one or more pharmaceutically acceptable excipients. Further, the present invention relates to stable pharmaceutical composition of ferric citrate or a pharmaceutically acceptable salt which improves patient compliance by enhancing ease of administration of the above mentioned pharmaceutical composition. Moreover, the present invention describes the methods employed for manufacturing the above mentioned oral pharmaceutical composition of ferric citrate.Type: ApplicationFiled: December 31, 2018Publication date: March 18, 2021Inventors: Parva Yogeshchandra PUROHIT, Paras Rasiklal VASANANI, Ashokkumar Hajabhai BARIA, Hinal Nitinkumar PATEL, Krunal Ashokbhai GOYANI
-
Publication number: 20200397756Abstract: The present invention relates to stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogen drug substances suitable for administration for the treatment of prostate cancer. The present invention particularly relates to stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogen (NSAA) drug substances for desirable pharmacokinetic and better patient compliance.Type: ApplicationFiled: February 8, 2019Publication date: December 24, 2020Inventors: Parva Yogeshchandra PUROHIT, Paras Rasiklal VASANANI, Riteshkumar Baldevbhai GURJAR, Nisha Ganapatbhai PATEL
-
Publication number: 20200222402Abstract: The present invention relates to a stable orally disintegrating pharmaceutical formulation comprising imatinib or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. The present invention further relates to a stable dispersible pharmaceutical formulation comprising imatinib or a pharmaceutically acceptable salt thereof, and a one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: July 16, 2018Publication date: July 16, 2020Applicant: KASHIV BIOSCIENCES, LLCInventors: Parva Yogeshchandra Purohit, Paras Rasiklal Vasanani, Vikas Maheshbhai Agrawal, Kiran Dilipbhai Patel
-
Publication number: 20200222310Abstract: The present invention relates to a pharmaceutical composition comprising glucosylceramide synthase inhibitor and a one or more pharmaceutically acceptable excipients. The present invention specifically relates to a sublingual pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. Moreover, the present invention further relates to a pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof which is used in the treatment of individual with lysozymal storage diseases selected from the group consisting of, Gaucher disease, Sphingolipidoses, Farber disease, Krabbe disease, Fabry disease, Schindler disease, Tay-Sachs disease and Niemann-Pick disease.Type: ApplicationFiled: February 14, 2020Publication date: July 16, 2020Applicant: KASHIV BIOSCIENCES, LLCInventors: Parva Yogeshchandra Purohit, Paras Rasiklal Vasanani, Vikas Maheshbhai Agrawal, Kishan Pradipbhai Suchak, Sandip Pareshbhai Mehta
-
Publication number: 20200197366Abstract: The present invention relates to a pharmaceutical composition comprising glucosylceramide synthase inhibitor and a one or more pharmaceutically acceptable excipients. The present invention specifically relates to a sublingual pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. Moreover, the present invention further relates to a pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof which is used in the treatment of individual with lysozymal storage diseases selected from the group consisting of, Gaucher disease, Sphingolipidoses, Farber disease, Krabbe disease, Fabry disease, Schindler disease, Tay-Sachs disease and Niemann-Pick disease.Type: ApplicationFiled: August 6, 2018Publication date: June 25, 2020Applicant: KASHIV BIOSCIENCES, LLCInventors: Parva Yogeshchandra Purohit, Paras Rasiklal Vasanani, Vikas Maheshbhai Agrawal, Kishan Pradipbhai Suchak
-
Publication number: 20140044781Abstract: The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: Amneal Pharmaceuticals, LLCInventors: Jatin Desai, Vipul Rasikbhai Gajjar, Gaurav Navinbhai Mistry, Parva Yogeshchandra Purohit
-
Publication number: 20110229564Abstract: The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet.Type: ApplicationFiled: March 18, 2011Publication date: September 22, 2011Applicant: Amneal Pharmaceuticals, L.L.C.Inventors: Jatin Desai, Vipul Rasikbhai Gajjar, Gaurav Navinbhai Mistry, Parva Yogeshchandra Purohit